## TMO: Thermo Fisher Scientific Inc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.5% below STRENGTH zone (3.0-6.0%); PEG 2.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($542.78)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Thermo Fisher Scientific Stock (TMO) After Hours: Key News, Analyst Forecasts, and What to Watch Before the Market Opens on Dec. 19, 2025**
- Source: ts2.tech | 20251219T024044 | Somewhat-Bullish | Relevance: 100%
- Thermo Fisher Scientific Inc. (TMO) closed nearly flat on Thursday, December 18, 2025, and remained stable in after-hours trading, trading around $562.40. The company announced the enrollment of the first patient in its new PPD™ CorEvitas™ Alzheimer’s Disease Registry, reinforcing its "picks-and-shovels" investment thesis in life sciences. Ahead of Friday's open, investors should monitor extended-hours activity, upcoming economic releases, Federal Reserve commentary, and key price levels, with macro factors like inflation signals expected to be the primary drivers for the stock's performance.

**2. Thermo Fisher Scientific (TMO) Stock Today: Alzheimer’s Registry Launch, Analyst Price Targets, and 2026 Catalysts (Dec. 18, 2025)**
- Source: ts2.tech | 20251218T211529 | Somewhat-Bullish | Relevance: 100%
- Thermo Fisher Scientific (NYSE: TMO) is in focus today due to the launch of its PPD CorEvitas Alzheimer’s Disease Registry, an initiative to gather real-world evidence for neurodegenerative care. The stock is trading around $561, with Wall Street analysts generally constructive on the company, maintaining "Moderate Buy" ratings and average 1-year price targets around $616-$631. The article also reviews Thermo Fisher's Q3 2025 performance, raised 2025 guidance, recent acquisitions, and upcoming catalysts for 2026.

**3. Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World E**
- Source: PharmiWeb.com | 20251218T154236 | Bullish | Relevance: 100%
- Thermo Fisher Scientific has launched the PPD CorEvitas Alzheimer’s Disease Registry, an international initiative designed to generate robust real-world data on Alzheimer's drug safety and effectiveness. This registry will provide a comprehensive understanding of Alzheimer's therapy outcomes, long-term safety, and treatment patterns, addressing a significant public health challenge where millions are affected. The initiative aims to support the development of current and next-generation therapies by providing regulatory-grade evidence.

**4. 2,959 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Montecito Bank & Trust**
- Source: MarketBeat | 20251218T120449 | Somewhat-Bullish | Relevance: 100%
- Montecito Bank & Trust recently acquired 2,959 shares of Thermo Fisher Scientific Inc. (NYSE:TMO) valued at approximately $1.435 million in Q3, contributing to the stock's 89.23% institutional ownership. Thermo Fisher reported strong Q3 earnings, beating estimates with an EPS of $5.79 and revenue of $11.12 billion, and authorized a $5.0 billion share buyback program. Despite significant insider selling, including the COO's sale of 22,046 shares, analysts maintain a "Moderate Buy" rating for TMO with an average target price of $616.60.

**5. Thermo Fisher Scientific Inc. (NYSE:TMO) Given Average Recommendation of "Moderate Buy" by Brokerages**
- Source: MarketBeat | 20251218T080841 | Bullish | Relevance: 100%
- Twenty-four brokerages have given Thermo Fisher Scientific Inc. (NYSE:TMO) an average recommendation of "Moderate Buy," with an average one-year price target of $616.60. The company recently surpassed Q3 earnings and revenue estimates and announced a $5.0 billion share buyback program along with a $0.43 quarterly dividend. Despite some insider selling, institutional investors have increased their holdings, reflecting confidence in the company.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $675 | $635 | +6% |
| 2025-12-11 | Citigroup | $660 | $580 | +14% |
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Overweight |
| 2025-12-11 | Citigroup | up | Buy |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($8.01M) |
| Sells | 12 ($5.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.6% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.3M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.12 elevated, pricing in significant growth expectations. Forward P/E 23.0x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (4 raises, avg +11%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $213.3B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.12 |
| Forward P/E | 23.0 |
| Current P/E | 25.0 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.1% to -0.5% (-2.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.5pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). MACD histogram bearish (-2.59), momentum weakening. RSI neutral at 47. OFD pattern: +STH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.50% (CS: 46) | Neutral |
| RSI_14 | 47.2 | Neutral |
| MACD Histogram | -2.59 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 1.000x | Below |
| vs SMA200 | 1.174x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $567.28
- **Stop Loss:** $542.78 (4.3% risk)
- **Target:** $591.78 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 48
- **Position Value:** $27,229.44
- **Portfolio %:** 27.23%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*